Platelet Dysfunction Because of Amlodipine in Bone Marrow Transplant Recipient.

Authors :: Gözmen S
Gözmen ŞK
Source :: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2022 Mar 01; Vol. 44 (2), pp. e467-e468.
Publication Year :: 2022
Abstract: Background: Hypertension (HTN) is a complication of pediatric hematopoietic stem cell transplantation. We report a pediatric stem cell transplant patient who had HTN and adverse event because of amlodipine.<br />Observation: Seven-year-old boy had haploidentical stem cell transplantation with post-transplant cyclophosphamide. He had complete donor chimerism at the end of one month. Amlodipine was started on day +36 for HTN. On day +41, he had petechiae. Platelet function analyzer (PFA)-100 was abnormal. After amlodipine was stopped, petechiae disappeared and PFA-100 returned to normal.<br />Conclusions: Abnormal PFA-100 and the patient complaints indicated the possibility of amlodipine-induced platelet dysfunction through inhibition of calcium-mediated platelet reactions.<br />Competing Interests: The authors declare no conflict of interest.<br /> (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)